Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 8,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: RSV Immunization
Interventions: RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 12 Months
Enrollment: 2,226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 66
States / cities: Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more

Conditions: Sarcopenia
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Iron Deficiency, Anemia
Interventions: Fer-in-Sol, control; Dietary Supplement · Other
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 4 Weeks to 9 Months
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Choroidal Neovascularization, Wet Macular Degeneration
Interventions: ICON-1, aflibercept; Biological
Lead sponsor: Iconic Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Beverly Hills, California • Santa Ana, California • Syracuse, New York + 5 more

Conditions: Wiskott-Aldrich Syndrome
Interventions: Patient Interview guide, Caregiver interview guide, Sociodemographic questionnaire, Pediatric quality of life (PedsQL) questionnaire, Clinical questionnaire; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 30 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Collegeville, Pennsylvania

Conditions: Hypocalcemia, Pseudohypoparathyroidism, Osteomalacia, Rickets, Pseudopseudohpoparathyroidism
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Months to 100 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Hypertension, Sickle Cell Disease, Thalassemia
Interventions: L-Glutamine; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 4 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Oakland, California

Conditions: ADHD
Interventions: Amphetamine Extended Release (ER) Tablet 20 mg; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 25 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperemesis Gravidarum
Interventions: Metformin Extended Release Oral Tablet; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Birmingham, Alabama • Los Angeles, California

Conditions: Neural Tube Defects, Folic Acid Deficiency, Spina Bifida, Anencephaly-Spina Bifida
Interventions: Folic acid fortified iodized salt; Dietary Supplement
Lead sponsor: Hydrocephalus and Neuroscience Institute; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: CARDIOMETABOLIC CONDITIONS, Obesity, Pre-diabetes, Metabolic Syndrome, Type2diabetes, Hypertension, Dyslipidemias
Interventions: Base intervention, Augmented Intervention; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years to 74 Years
Enrollment: 1,029 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: Wet AMD
Interventions: Not listed
Lead sponsor: West Coast Retina Medical Group, Inc.; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cerebral Palsy (CP)
Interventions: Soterix 1x1 tDCS LTE Stimulator Device Model 1401; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 8 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: Lucentis (Ranibizumab); Drug
Lead sponsor: University of Miami; Other
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Writer's Cramp, Healthy Volunteers, Cervical Dystonia
Interventions: TMS; Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer, Advanced Adenocarcinoma, Serrated Polyp
Interventions: ColoSense; Diagnostic Test
Lead sponsor: Geneoscopy, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 14,263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: St Louis, Missouri • Austin, Texas

Conditions: Mantle Cell Lymphoma
Interventions: Venetoclax, Bendamustine, Rituximab; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 60 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Urbana, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 4 more

Conditions: Osteoarthritis, Knee, Hypertension
Interventions: STAR Intervention, Attention-Control; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypochondroplasia
Interventions: Vosoritide, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 0 Months to 36 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 7 more

Conditions: Multiple Myeloma
Interventions: Plinabulin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Glycogen Storage Disease Type III
Interventions: No Intervention; Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 1 Year and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Houston, Texas

Conditions: Cystic Fibrosis
Interventions: LUM/IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 17
States / cities: Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more

Conditions: Major Depressive Disorder (MDD), Healthy Adult Volunteer
Interventions: Hot Cognitive Task, Cold cognitive tasks, Structural magnetic resonance imaging (sMRI), Magnetoencephalography imaging (MEG), four self-report forms per the requirement of the NIH Common Data Elements project, Four self-report measures to assess interpersonal functioning, Clinical assessments, ATHF; Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Arlington, Texas • Dallas, Texas

Conditions: Chronic Graft Versus Host Disease
Interventions: Ibrutinib; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 1 Year to 21 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 20
States / cities: Duarte, California • San Diego, California • San Francisco, California + 17 more

Search by objective public record fields.

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Blood Flow, Muscle Regeneration and Sarcopenia

Prevention of Iron Deficiency in Breastfed Infants

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)

Studies of States With Resistance to Vitamin D and Parathyroid Hormone

Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension

Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)

Hyperemesis Gravidarum Risk Reduction With Metformin

Salt-FA to Increase Folate Levels

The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older

Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy

Pediatric Teleneuromodulation

Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)

Propensity to Develop Plasticity in the Parieto-Motor Networks in Dystonia From the Perspective of Abnormal High-Order Motor Processing

Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Staying Active With Arthritis: RCT of Physical Activity for Older Adults With Osteoarthritis and Hypertension

A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)